Nyxoah S.A.
NYXH • Medical - Specialties
$0.94
— 0.00 (0.00%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$40.62M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 64.6%Manageable debt level · 0.86Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.94
Change0.00%
Shares Out43.21M
Market Cap$40.62M
52W Range1.26 - 8.59
Beta0.62
P/E-0.89
P/S8.88
P/B1.81
P/FCF-2.92
EV/Sales17.98
EV/EBITDA-6.09
Price$0.94
Change0.00%
Shares Out43.21M
Market Cap$40.62M
52W Range1.26 - 8.59
Beta0.62
P/E-0.89
P/S8.88
P/B1.81
P/FCF-2.92
EV/Sales17.98
EV/EBITDA-6.09
EV/FCF-5.92
Earnings Yield-28.19%
FCF Yield-34.22%
Dividend Yield0.00%
Gross Margin63.13%
Oper. Margin-8.28%
Profit Margin-8.99%
Debt/Eq0.86
Current Ratio1.25
Quick Ratio1.16
Target$4.08
Target Upside334.04%
Target Median$3.50
Target Range2.31 - 7.00
Volume100.53K
Avg Volume256.13K
EPS Surprise0.11
Investment DNA
How strong this company looks for long-term investors
45
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
59/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
49/100
Why this score▼
Positive revenue growth · 64.6%Manageable debt level · 0.86Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-10-20
90/100
Bullish
Bullish
4
Hold
1
Bearish
0
Price Target
2026-06-24
Low
$3.00
Mean
$5.00
Median
$5.00
High
$7.00
🧾
No insider activity
No recent insider transactions available.